Tag: Abbott

CUTTING-EDGE registry data sheds light on surgical outcomes following failed transcatheter edge-to-edge repair

Gilbert Tang (New York, USA) talks to Cardiovascular News about the key findings from the CUTTIN...

EXPAND registry outcomes of new MitraClip devices in line with COAPT

 Jörg Hausleiter (Munich, Germany) talks to Cardiovascular News about the one-year findings of ...

Transcatheter tricuspid valve repair shows promise for reducing heart failure hospitalisations

In JACC: Heart Failure, Mathias Orban (Medizinische Klinik und Poliklinik I, Klinikum der Univer...

CE mark for transcatheter system that uses same clip technology as MitraClip

Abbott has received the CE mark for its TriClip transcatheter tricuspid valve repair system. It ...
MitraClip in moderate surgical risk patients

Virtual ACC: Newer generations of MitraClip associated with greater reduction in mitral regurgitation than previous version

Today at the American College of Cardiology/World Congress of Cardiology’s virtual scientific se...

FDA Breakthrough Device Designation for fully implantable left ventricular assist system

The US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Abbott ...

Abbott becomes first company in world to have transcatheter mitral implantation device on market

The Tendyne transcatheter mitral valve implantation (TMVI) system (Abbott) has received the CE mark,...

Abbott starts trial to evaluate TriClip for percutaneous repair of tricuspid regurgitation

Abbott has announced its TRILUMINATE pivotal trial to evaluate the safety and effectiveness of t...

ESC 2019: Two-year findings of MITRA-FR continue to show no prognosis benefit with MitraClip

At the European Society of Cardiology Congress (ESC 2019; 31 August–4 September, Paris, France),...

Fourth-generation MitraClip receives FDA approval

According to a statement, Abbott has announced it has received US Food and Drug Administration (...
MitraClip in moderate surgical risk patients

MitraClip can be used to treat secondary mitral regurgitation in the USA

The US FDA has approved a new indication for percutaneous edge-to-edge repair (MitraClip, Abbott...

CRT 2019: US FDA approves resting full-cycle ratio for measuring severity of coronary artery blockages

Abbott has announced the US FDA clearance of the resting full-cycle ratio (RFR) diagnostic test to i...

Abbott to acquire Cephea Valve Technologies

It was recently announced that Abbott has exercised its option to purchase Cephea Valve Technologies...

FDA approves world’s first device for treatment of premature babies and newborns with an opening in their hearts

The US Food and Drug Administration (FDA) has approved the Amplatzer Piccolo Occluder (Abbott), ...

US FDA approve HeartMate 3 heart pump for advanced heart failure patients not eligible for a heart transplant

The HeartMate 3 left ventricular assist device has received US FDA approval as a destination the...

TCT 2018: One-year real-world results show Portico TAVI system reduces severe aortic stenosis

According to one-year results from the PORTICO I study, which were presented during a late-breaking ...

ESC 2018: MitraClip makes “absolutely no difference” for the prognosis of secondary mitral valve regurgitation

The first randomised controlled trial to compare percutaneous edge-to-edge repair (MitraClip, Ab...

Abbott launches trial of its Tendyne transcatheter mitral valve implantation device

Abbott has initiated a pivotal clinical study in the USA of its Tendyne transcatheter mitral val...
MitraClip in moderate surgical risk patients

Next-generation of MitraClip approved for use in the USA

Abbott has received approval from the US FDA for a next-generation version of its MitraClip hear...

Xience Sierra approved for use in USA

Abbott has announced it has received approval from the US FDA for its Xience Sierra, the newest ...

FDA approves the world’s smallest mechanical heart valve

The US FDA has approved the Masters HP 15mm rotatable mechanical heart valve (Abbott), which a p...

First patient enrolled in trial reviewing 28-day DAPT with Xience

The first patient has been enrolled in a clinical trial evaluating 28 days of dual antiplatelet ...

TCT 2017: Advances in device technology needed to improve outcomes with Absorb

Data from the ABSORB IV study indicate that device thrombosis with the bioresorbable vascular sc...

MitraClip becomes first approved device for transcatheter mitral valve repair in Japan

Abbott has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved its...

Abbott’s Full MagLev HeartMate 3 LVAD receives FDA approval

The FDA has approved the Full MagLev HeartMate 3 (Abbott) left ventricular assist device for use...

US trial to evaluate safety and efficacy of Amplatzer for patent ductus arteriosus

Abbott has initiated a US pivotal clinical study evaluating the safety and effectiveness of a mo...

Millipede 50mm annuloplasty ring used in first cases

Millipede has announced the successful implantation of its newest 50mm Iris annuloplasty ring, w...

ACC 2017: CardioMEMS HF system effective in reducing heart failure hospitalisations and cost of care

Late-breaking clinical research presented at the American College of Cardiology 66th Annual Scie...
DAPT

Terumo signs to acquire St Jude Medical and Abbott’s vascular closure business

Terumo has reached an agreement with Abbott and St Jude Medical to acquire certain products owned by...

St. Jude Medical and Abbott to sell portion of vascular closure and electrophysiology businesses to Terumo

Abbott and St. Jude Medical have announced an agreement in principle to sell certain products to...